Skip to Content

Vanderbilt-Ingram Cancer CenterVanderbilt-Ingram Cancer Center

 

VICC toll-free number 1-877-936-8422

Clinical Trials for Bortezomib (BTZ)

4 Open Trials

Trial Type Protocol No. &
Open Date
Summary

Treatment

VICCHEM1377

03/14/2014

A Phase 1 Study of Arry-520 and Bortezomib plus Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma

Treatment

VICCHEM12107

03/31/2013

A Phase 3, Multicenter, Randomized, Open-label Study to Compare the Efficacy and Safety of Pomalidomide (POM), Bortezomib (BTZ) and Low-Dose Dexamethasone (LD-DEX) versus Bortezomib and Low-Dose Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma (MM)

Treatment

ECOGHEME2408

05/10/2011

A 3-Arm Randomized Phase II Trial of Bendamustine-Rituximab (BR) Followed by Rituximab vs Bortezomib-BR (BVR) Followed by Rituximab vs BR Follwed by Lenalidomide/Rituximab in High Risk Follicular Lymphoma

Treatment

VICCBMT1020

11/15/2010

Impact of First Autologous Transplant on Minimal Residual Disease Markers in Previously Untreated Myeloma Undergoing Initial Treatment with Velcade Based Therapy